PDF version here 

BLUMORPHO innovation accelerator and CEA-LETI received the “Best Early Stage Innovation” prize for their new generation of MagnetoEncephaloGraphy (MEG)

Every year, the famous European Commission’s Innovation Radar submits to the vote of European citizens a selection of EU-funded innovations in order to choose the one they find the more promising. 5 different categories are represented in the panel: Industrial & Enabling Tech, Excellent Science, Best Young SME, Tech for Society and Best Early Stage Innovation.

Among the 2017 finalists in the “Best Early Stage Innovation” category, the European Commission and the European citizens had identified innovations in artificial intelligence and enabling technology from CEA-LETI for a new generation of MagnetoEncephaloGraphy (MEG). This breakthrough technology in Brain imaging finally won the prize on Tuesday 9th November, during the ICT’s Proposers’ Day in Budapest.
The development of this innovation was performed in the framework of the Gateoneproject, one of the first BLUMORPHO Factory’s innovation acceleration program. Thanks to this project, the technology research institute CEA-LETI developed the new quantum sensor that allows this real breakthrough in Brain Imaging and MagnetoEncephaloGraphy. Meanwhile, the European innovation accelerator BLUMORPHO build a complete value chain for this innovation to reach its market.

The Magnetometers

The magnetometers from CEA-LETI were initially developed for the spatial sector and had proved to be maintenance-free. Thanks to BLUMORPHO’s knowledge in cross-fertilization and to CEA-LETI’s expertise, the investment in the Gateone-project led to a 4 times improvement of the sensor performance which makes it now usable in MEG. This innovation will reduce the current cost of an extremely expensive technology by a factor of 5 to 6. With this innovation, BLUMORPHO, and CEA-LETI will disrupt the MEG market. These devices will address Epilepsy first. 6 Million People in Europe are living with Epilepsy, 30% are drug-resistant. This new MEG generation can diagnose better, and increase the access to neurosurgery. MEG can also detect early dysfunction of the brain in Alzheimer’s Disease. But this is just the beginning. Neuromedicine is following multiple roadmaps with non-invasive surgery and regenerative medicine. This new generation of MEG equipment will deliver visualization of brain activity to support such evolution and make it happen.

“This innovation award is an important milestone for the launch of a future product. It will enable us to increase the awareness of the neuro medical community on the future availability of MEG new generation. This innovation will push existing limits to diagnose and cure brain disorders. 165 000 000 people are concerned in Europe. It is one of the biggest challenges we are facing” said Regis Hamelin, BLUMORPHO CTO, and Gateone-project project coordinator.

BLUMORPHO and CEA-LETI are very proud and very honored that this sensor received this Innovation Radar Prize 2017 as the best early-stage innovation.

“This award is a very strong and positive recognition of our dedication to supporting early-stage Innovation at a pan European-level,” said Geraldine Andrieux Gustin, CEO of BLUMORPHO.


BLUMORPHO is a Private Digital Innovation Hub accelerating innovation while driving New Product Introduction programs based on Lean and Open Innovation. BLUMORPHO operates in Deep Tech, Digital and Smart systems, addressing more than 24 different vertical businesses.

Based on its recognized technical and business expertise, as well as its global network composed by more than 60 000 contacts, BLUMORPHO generates high valuable innovation for any company looking for a new product, new business model, new technology or new market. BLUMORPHO is accelerating the transition from technology to market adoption in structuring the relevant value chain. Its team is working hands-on to develop innovation with high differentiation that will make a difference in the market place.

About Gate one-project

Gateone-project co-funded by the European Commission under the grant agreement 644856 – H2020-ICT-2014-1 is one of the first innovation acceleration program developed by BLUMORPHO. Gateone-project is part of the Smart Anything Everywhere initiative. In the scope of this acceleration program, 50 demonstrators integrating smart systems have been developed. Those demonstrators enabled European SMEs to reinforce their differentiation and market positioning while generating value.


Leti, a technology research institute at CEA Tech, is a global leader in miniaturization technologies enabling smart, energy-efficient and secure solutions for industry. Founded in 1967, Leti pioneers micro-& nanotechnologies, tailoring differentiating applicative solutions for global companies, SMEs and startups. Leti tackles critical challenges in healthcare, energy and digital migration. From sensors to data processing and computing solutions, Leti’s multidisciplinary teams deliver solid expertise, leveraging world-class pre-industrialization facilities. With a staff of more than 1,900, a portfolio of 2,700 patents, 91,500 sq. ft. of cleanroom space and clear IP policy, the institute is based in Grenoble, France, and has offices in Silicon Valley and Tokyo. Leti has launched 60 startups and is a member of the Carnot Institutes network. This year, the institute celebrates its 50th  anniversary.

CEA Tech is the technology research branch of the French Alternative Energies and Atomic Energy Commission (CEA), a key player in innovative R&D, defense & security, nuclear energy, technological research for industry and fundamental science, identified by Thomson Reuters as the second most innovative research organization in the world. CEA Tech leverages a unique innovation-driven culture and unrivaled expertise to develop and disseminate new technologies for industry, helping to create high-end products and provide a competitive edge.

This innovation is one of the 50 demonstrators developed in our acceleration program covering 24 different vertical businesses. For more information contact us or request a meeting.